CheckMate 649 Gastric — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Nivolumab + chemotherapy significantly improved OS and PFS compared with chemotherapy alone in PD-L1 CPS ≥5 advanced gastric/GOJ/oesophageal adenocarcinoma
CheckMate 649 (Janjigian et al Lancet 2021): nivo + chemo vs chemo in advanced G/GOJ/oesophageal adeno. CPS ≥5: OS 14.4 vs 11.1 months. Established nivolumab + chemo as first-line for CPS ≥5 gastric cancer. NICE approved.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer